Cypress Capital Group Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$2.15M |
| 2 |
iShares MSCI EAFE Min Vol Factor ETF
EFAV
|
+$2.03M |
| 3 |
Intuit
INTU
|
+$1.62M |
| 4 |
DXC Technology
DXC
|
+$1.42M |
| 5 |
S&P Global
SPGI
|
+$1.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$1.95M |
| 2 |
Ross Stores
ROST
|
+$1.66M |
| 3 |
TJX Companies
TJX
|
+$1.27M |
| 4 |
iShares Core S&P Small-Cap ETF
IJR
|
+$1.08M |
| 5 |
PBCT
People's United Financial Inc
PBCT
|
+$1.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.09% |
| 2 | Consumer Staples | 12.96% |
| 3 | Technology | 10.84% |
| 4 | Financials | 9.95% |
| 5 | Industrials | 9.36% |
Similar funds
Cypress Capital Group's Q2 2017 Portfolio in Review
As of Q2 2017, Cypress Capital Group held 215 positions worth $452M, up 5.5% from $428M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Cypress Capital Group deployed $16M of net new capital in Q2 2017, opening 29 new positions and adding to 52 existing holdings. Its largest new stake was iShares Core MSCI Emerging Markets ETF: 43,552 shares worth $2.18M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 16% a quarter earlier, followed by Consumer Staples and Technology.
On the sell side, the largest reduction was Pfizer, an estimated $1.95M trimmed.
- Cypress Capital Group's largest Q2 2017 buy was iShares Core MSCI Emerging Markets ETF: 43,552 shares worth $2.18M.
- Cypress Capital Group added most to Intuit in Q2 2017, an estimated $1.62M increase.
- Cypress Capital Group's biggest Q2 2017 reduction was Pfizer, cutting an estimated $1.95M.
- Cypress Capital Group fully exited NOV in Q2 2017, selling an estimated $567K.
- Cypress Capital Group's ten largest holdings make up 24% of its $452M portfolio in Q2 2017.
- Cypress Capital Group opened 29 new positions and closed 14 in Q2 2017.
- Cypress Capital Group's portfolio value rose 5.5% quarter-over-quarter to $452M.
Based on Cypress Capital Group's 13F filing for Q2 2017, filed 15 Aug 2017.